A combination screening to identify enhancers of para-aminosalicylic acid against Mycobacterium tuberculosis

Sci Rep. 2022 Apr 4;12(1):5635. doi: 10.1038/s41598-022-08209-w.

Abstract

Para-aminosalicylic acid (PAS) is an antibiotic that was largely used for the multi-therapy of tuberculosis in the twentieth century. To try to overcome the inconvenience of its low efficacy and poor tolerance, we searched for novel chemical entities able to synergize with PAS using a combination screening against growing axenic Mycobacterium tuberculosis. The screening was performed at a sub-inhibitory concentration of PAS on a library of about 100,000 small molecules. Selected hit compounds were analyzed by dose-response and further probed with an intracellular macrophage assay. Scaffolds with potential additive effect with PAS are reported, opening interesting prospects for mechanism of action studies. We also report here evidence of a yet unknown bio-activation mechanism, involving activation of pyrido[1,2-a]pyrimidin-4-one (PP) derivatives through the Rv3087 protein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminosalicylic Acid* / metabolism
  • Aminosalicylic Acid* / pharmacology
  • Antitubercular Agents / chemistry
  • Humans
  • Mycobacterium tuberculosis*
  • Tuberculosis, Lymph Node*

Substances

  • Antitubercular Agents
  • Aminosalicylic Acid